KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Current Assets: 2009-2024

Historic Current Assets for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $1.1 billion.

  • Halozyme Therapeutics' Current Assets rose 17.90% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 17.90%. This contributed to the annual value of $1.1 billion for FY2024, which is 45.41% up from last year.
  • Halozyme Therapeutics' Current Assets amounted to $1.1 billion in FY2024, which was up 45.41% from $746.4 million recorded in FY2023.
  • Over the past 5 years, Halozyme Therapeutics' Current Assets peaked at $1.1 billion during FY2024, and registered a low of $554.8 million during FY2020.
  • Its 3-year average for Current Assets is $856.9 million, with a median of $746.4 million in 2023.
  • As far as peak fluctuations go, Halozyme Therapeutics' Current Assets skyrocketed by 66.97% in 2021, and later declined by 20.22% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Current Assets (Yearly) stood at $554.8 million in 2020, then soared by 66.97% to $926.3 million in 2021, then fell by 20.22% to $739.0 million in 2022, then climbed by 1.00% to $746.4 million in 2023, then spiked by 45.41% to $1.1 billion in 2024.